Compare Invesco NASDAQ 100 ETF (QQQM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco NASDAQ 100 ETF vs Recursion Pharmaceuticals Inc — how do they compare? Invesco NASDAQ 100 ETF trades at $309.1 (market cap $113.40B), while Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 53× Recursion Pharmaceuticals Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco NASDAQ 100 ETF for 54 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| QQQM | RXRX | |
|---|---|---|
Market Cap | $113.40B | $2.14B |
Volume | 2,866,236 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $312.76 | $6.79 |
52-Week Low | $229.87 | $2.84 |
Typical Hold Time | 54 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQM trades at $308.42, down 1.15% on the day, while maintaining a bullish technical outlook with strong moving average support. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026, signaling confidence in the Nasdaq-100 exposure.
The ETF offers pure Nasdaq-100 exposure with competitive fees, though investors should be aware of concentration risk in technology stocks and potential tax implications of distributions. Technical indicators suggest near-term support at $305 with resistance at $311, while institutional accumulation supports the bullish case for long-term growth investors.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
